ClinicalTrials.gg
CompletedNCT02457793Updated Nov 20, 2018Results posted

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Cobimetinib and GDC-0994 in Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma, sponsored by Genentech, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-20.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Enrollment
120th of 142
24 · median 136
Started
2015
with 8 others
Phase 1
19 of 182
1 open now
Registered
108th of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 120th largest by enrollment of the 142 interventional ones that give a count, is one of 9 that started in 2015, is one of 19 in phase 1, and was the 108th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.

03

Conditions studied

  • Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status of 0 or 1
  • or cytologically documented, locally advanced or solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable
  • Evaluable disease or disease measurable
  • > or = 12 weeks
  • Adequate hematologic and end organ function
  • For female patients of and male patients with partners of childbearing potential, use of an effective form of with continued use for study duration and up to 3 months or more following discontinuation of treatment drug
  • Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan

For enrollment in part 2, patients must meet all of the following:

  • No more than four prior systemic therapies for locally advanced or metastatic cancer

Exclusion criteria

Exclusion Criteria:

  • History of prior significant toxicity from another MEK inhibitor or ERK inhibitor requiring discontinuation of treatment
  • Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis
  • History of glaucoma
  • Intraocular pressure > 21 mmHg as measured by tonometry
  • Predisposing factors to retinal vein occlusion (RVO)
  • History of RVO, neurosensory retinal detachment, or neovascular macular degeneration
  • Allergy or to components of the cobimetinib or GDC-0994 formulation
  • Palliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1
  • Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1
  • Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment
  • Anti-cancer therapy within 28 days prior to the first dose of study-drug treatment in Cycle 1
  • Current severe, uncontrolled systemic disease
  • History of cardiac dysfunction
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1
  • History of congenital long syndrome or QTc > 470 msec
  • History of malabsorption or other condition that would interfere with enteral absorption
  • Clinically significant history of liver disease, current alcohol abuse, or current known active infection with , virus, or virus
  • Any condition requiring warfarin or thrombolytic anticoagulants
  • Active disease
  • Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment
  • Pregnancy, lactation, or breastfeeding
  • Known that are untreated, symptomatic, or require therapy to control symptoms
  • No other history of or ongoing that would potentially interfere with the interpretation of the Pharmacodynamic (PD) or efficacy assays
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Not assigned

    One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.

    Drug: Cobimetinib · Drug: GDC-0994

  • Experimental
    COB 20 mg + GDC 200 mg

    Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.

    Drug: Cobimetinib · Drug: GDC-0994

  • Experimental
    COB 40 mg + GDC 200 mg

    Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.

    Drug: Cobimetinib · Drug: GDC-0994

  • Experimental
    COB 80 mg + GDC 200 mg

    Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.

    Drug: Cobimetinib · Drug: GDC-0994

  • Experimental
    COB 80 mg + GDC 400 mg

    Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.

    Drug: Cobimetinib · Drug: GDC-0994

  • Experimental
    COB 100 mg + GDC 200 mg

    Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.

    Drug: Cobimetinib · Drug: GDC-0994

Interventions

  • Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

  • DrugGDC-0994

    GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs)

    DLTs include symptoms considered by the investigator to be possibly related to study drug.

    Time frame: 28 days (Cycle 1)

  2. Percentage of Participants With at Least One Adverse Event

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

    Time frame: Up to 15 months

  3. Percentage of Participants With at Least One Adverse Event of Special Interest

    AESIs were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. AESIs included the following: Grade ≥ 1 retinal vein occlusion; Grade ≥ 2 visual disturbances (including events suggestive of serous retinopathy); Grade ≥ 3 rash for \> 7 days; Grade ≥ 3 diarrhea for \> 3 days; Grade ≥ 2 left ventricular ejection fraction (LVEF) decrease; Grade 3 hepatotoxicity; any dose-limiting toxicity (DLT); cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST \> 3 × baseline value \[and above the upper limit of normal, ULN\]) in combination with either an elevated bilirubin ( \> 2 × ULN) or clinical jaundice; or suspected transmission of an infectious agent by either study drug.

    Time frame: Up to 15 months

  4. Percentage of Participants With at Least One Serious Adverse Event (SAE)

    A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.

    Time frame: Up to 15 months

  5. Percentage of Participants With Laboratory Abnormalities

    Laboratory abnormalities were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. SGPT/ALT - serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST - serum glutamic oxaloacetic transaminase/aspartate aminotransferase

    Time frame: Up to 15 months

  6. Mean Change From Baseline in Diastolic Blood Pressure

    Time frame: Baseline, up to 15 months

  7. Mean Change From Baseline in Lean Body Mass

    Time frame: Baseline, Day 15

  8. Mean Change From Baseline in Pulse Rate

    Time frame: Baseline, up to 15 months

  9. Mean Change From Baseline in Respiratory Rate

    Time frame: Baseline, up to 15 months

  10. Mean Change From Baseline in Systolic Blood Pressure

    Time frame: Baseline, up to 15 months

  11. Mean Change From Baseline in Temperature

    Time frame: Baseline, up to 15 months

  12. Mean Change From Baseline in Weight

    Time frame: Baseline, up to 15 months

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) for GDC-0994

    Time frame: Up to Day 22

  2. Median Time to Maximum Serum Concentration (Tmax) for GDC-0994

    Time frame: Up to Day 22

  3. Maximum Serum Concentration (Cmax) for Cobimetinib

    Time frame: Up to Day 22

  4. Median Time to Maximum Serum Concentration (Tmax) for Cobimetinib

    Time frame: Up to Day 22

  5. Total Exposure (AUC From Time 0 to 24 Hour After Dose) for GDC-0994

    Data are reported for evaluable participants.

    Time frame: 0 to 24 hours post-dose (Up to Day 22)

  6. Total Exposure (AUC From Time 0 to 24 Hour After Dose) for Cobimetinib

    Time frame: 0 to 24 hours post-dose (Up to Day 22)

  7. Mean Accumulation Ratio

    Time frame: Pre-dose Day 1 Cycle 1, 2, 3, Day 18, 21 Cycle 1; post-dose 0.5, 1, 2, 3, 4, 6 hours Day 1, 18, 21 Cycle 1; Day 2, 15, 19, 22, Cycle 1

  8. Mean Terminal Half-life (t1/2)

    Time frame: Up to day 22 of study

  9. Change From Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

    Time frame: Baseline, Day 15

  10. Change From Baseline in Tumor Tissue Biomarkers

    Time frame: Up to 15 months

07

Results

Posted Aug 24, 2018

Participant flow

Participant flow — Overall Study
MilestoneNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Started153546
Completed010000
Not completed143546
Withdrew: Reason not specified000111
Withdrew: Withdrawal by subject042222
Withdrew: Adverse event000100
Withdrew: Physician decision101113

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs)

DLTs include symptoms considered by the investigator to be possibly related to study drug.

Time frame:
28 days (Cycle 1)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Dermatitis Acneiform100000
Rash100000
Diarrhoea001000
Myocardial infarction000100
PrimaryPercentage of Participants With at Least One Adverse Event

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.

Time frame:
Up to 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event
percentage of participantsNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Percentage of Participants With at Least One Adverse Event100100100100100100
PrimaryPercentage of Participants With at Least One Adverse Event of Special Interest

AESIs were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. AESIs included the following: Grade ≥ 1 retinal vein occlusion; Grade ≥ 2 visual disturbances (including events suggestive of serous retinopathy); Grade ≥ 3 rash for \> 7 days; Grade ≥ 3 diarrhea for \> 3 days; Grade ≥ 2 left ventricular ejection fraction (LVEF) decrease; Grade 3 hepatotoxicity; any dose-limiting toxicity (DLT); cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (AST \> 3 × baseline value \[and above the upper limit of normal, ULN\]) in combination with either an elevated bilirubin ( \> 2 × ULN) or clinical jaundice; or suspected transmission of an infectious agent by either study drug.

Time frame:
Up to 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event of Special Interest
percentage of participantsNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Percentage of Participants With at Least One Adverse Event of Special Interest100.010033.360.075.050.0
PrimaryPercentage of Participants With at Least One Serious Adverse Event (SAE)

A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.

Time frame:
Up to 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Serious Adverse Event (SAE)
percentage of participantsNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Percentage of Participants With at Least One Serious Adverse Event (SAE)100.040.066.760.050.066.7
PrimaryPercentage of Participants With Laboratory Abnormalities

Laboratory abnormalities were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0. SGPT/ALT - serum glutamic-pyruvic transaminase/alanine aminotransferase; SGOT/AST - serum glutamic oxaloacetic transaminase/aspartate aminotransferase

Time frame:
Up to 15 months
Reported as:
Number · percentage of participants
Percentage of Participants With Laboratory Abnormalities
percentage of participantsNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Albumin100.080.066.7100.0100.083.3
Alkaline Phosphatase100.080.066.780.075.050.0
SGPT/ALT0.060.00.060.025.033.3
SGOT/AST100.0100.066.760.075.050.0
Calcium100.020.033.380.0100.033.3
Creatinine100.0100.0100.0100.0100.050.0
Blood Glucose, Fasting0.0100.0100.00.066.6100.0
Gamma Glutamyl Transferase100.060.066.760.075.050.0
Glucose020.00.00.00.00.0
Hemoglobin100.060.066.7100.075.066.7
Lymphocytes, Absolute100.040.033.360.050.016.7
Magnesium100.040.066.620.050.016.7
Phosphorus0.020.00.00.025.00.0
Platelets0.020.033.340.050.033.3
Potassium0.040.066.740.025.033.3
Sodium0.060.033.30.050.016.7
Bilirubin100.020.00.00.025.00.0
Uric Acid0.020.00.00.025.016.7
White Blood Cell Count0.0200.020.025.033.3
PrimaryMean Change From Baseline in Diastolic Blood Pressure
Time frame:
Baseline, up to 15 months
Reported as:
Mean · millimeters of mercury (mmHg)
Mean Change From Baseline in Diastolic Blood Pressure
millimeters of mercury (mmHg)Not AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Diastolic Blood Pressure—-4.2 ± 7.6-4.3 ± 11.8-0.5 ± 7.829.0-13.2 ± 15.9
PrimaryMean Change From Baseline in Lean Body Mass
Time frame:
Baseline, Day 15
Reported as:
Mean · kilograms (kg)
Mean Change From Baseline in Lean Body Mass
kilograms (kg)Not AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Lean Body Mass—0.25 ± 1.26-2.00-0.20 ± 1.30-4.33 ± 5.770.00 ± 1.41
PrimaryMean Change From Baseline in Pulse Rate
Time frame:
Baseline, up to 15 months
Reported as:
Mean · beats per minute
Mean Change From Baseline in Pulse Rate
beats per minuteNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Pulse Rate—20.4 ± 32.716.7 ± 22.715.5 ± 9.243.012.2 ± 21.6
PrimaryMean Change From Baseline in Respiratory Rate
Time frame:
Baseline, up to 15 months
Reported as:
Mean · breaths per minute
Mean Change From Baseline in Respiratory Rate
breaths per minuteNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Respiratory Rate—1.6 ± 3.60.3 ± 0.60.0 ± 0.02.01.6 ± 3.6
PrimaryMean Change From Baseline in Systolic Blood Pressure
Time frame:
Baseline, up to 15 months
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure
mmHgNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Systolic Blood Pressure—2.2 ± 19.6-4.0 ± 30.6-1.5 ± 0.734.0-17.2 ± 20.9
PrimaryMean Change From Baseline in Temperature
Time frame:
Baseline, up to 15 months
Reported as:
Mean · degrees Celsius
Mean Change From Baseline in Temperature
degrees CelsiusNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Temperature—-0.04 ± 0.31-0.20 ± 0.87-0.16 ± 0.20-0.20-0.16 ± 0.34
PrimaryMean Change From Baseline in Weight
Time frame:
Baseline, up to 15 months
Reported as:
Mean · kg
Mean Change From Baseline in Weight
kgNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Mean Change From Baseline in Weight—-4.01 ± 7.710.33 ± 1.690.57 ± 3.34-2.70-0.80 ± 3.43
SecondaryMaximum Serum Concentration (Cmax) for GDC-0994
Time frame:
Up to Day 22
Reported as:
Geometric mean · micromoles
Maximum Serum Concentration (Cmax) for GDC-0994
micromolesCOB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—2.51 ± 54.62.08 ± 68.42.02 ± 109.02.42 ± 33.62.56 ± 77.8
Steady State2.561.80 ± 74.22.01 ± 0.02.26 ± 23.12.09 ± 0.02.36 ± 28.2
SecondaryMedian Time to Maximum Serum Concentration (Tmax) for GDC-0994
Time frame:
Up to Day 22
Reported as:
Mean · hours
Median Time to Maximum Serum Concentration (Tmax) for GDC-0994
hoursCOB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—4.00 (2.00 to 6.00)6.00 (2.00 to 6.00)3.00 (2.00 to 24.0)15.0 (2.0 to 24.0)2.50 (1.00 to 4.00)
Steady State3.003.00 (2.00 to 4.00)24.02.00 (2.00 to 3.00)3.002.00 (2.00 to 2.00)
SecondaryMaximum Serum Concentration (Cmax) for Cobimetinib
Time frame:
Up to Day 22
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Maximum Serum Concentration (Cmax) for Cobimetinib
nanograms per milliliter (ng/mL)COB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—41.8 ± 102.090.2 ± 60.9392 ± 31.9155 ± 52.5384 ± 53.2
Steady State73.048.5 ± 121.0204399 ± 46.4284431 ± 63.3
SecondaryMedian Time to Maximum Serum Concentration (Tmax) for Cobimetinib
Time frame:
Up to Day 22
Reported as:
Median · hours
Median Time to Maximum Serum Concentration (Tmax) for Cobimetinib
hoursCOB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—2.00 (2.00 to 4.00)2.00 (1.00 to 3.00)2.00 (1.00 to 3.00)4.00 (2.00 to 6.00)2.00 (1.00 to 3.00)
Steady State1.001.50 (1.00 to 2.00)24.01.00 (0.500 to 2.00)2.002.00 (2.00 to 2.00)
SecondaryTotal Exposure (AUC From Time 0 to 24 Hour After Dose) for GDC-0994

Data are reported for evaluable participants.

Time frame:
0 to 24 hours post-dose (Up to Day 22)
Reported as:
Geometric mean · hr x microM
Total Exposure (AUC From Time 0 to 24 Hour After Dose) for GDC-0994
hr x microMCOB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—37.0 ± 45.932.9 ± 55.427.9 ± 93.837.8 ± 37.537.7 ± 81.0
Steady State48.323.5 ± 73.424.133.3 ± 66.437.234.0
SecondaryTotal Exposure (AUC From Time 0 to 24 Hour After Dose) for Cobimetinib
Time frame:
0 to 24 hours post-dose (Up to Day 22)
Reported as:
Geometric mean · ng x hr/mL
Total Exposure (AUC From Time 0 to 24 Hour After Dose) for Cobimetinib
ng x hr/mLCOB 80 mg + GDC 300 mgCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
Day 1—501 ± 121.01020 ± 33.94420 ± 25.52460 ± 50.94060 ± 74.3
Steady State908508 ± 255.024604320 ± 37.434104070
SecondaryMean Accumulation Ratio
Time frame:
Pre-dose Day 1 Cycle 1, 2, 3, Day 18, 21 Cycle 1; post-dose 0.5, 1, 2, 3, 4, 6 hours Day 1, 18, 21 Cycle 1; Day 2, 15, 19, 22, Cycle 1

No measurements were reported for this outcome.

SecondaryMean Terminal Half-life (t1/2)
Time frame:
Up to day 22 of study

No measurements were reported for this outcome.

SecondaryChange From Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
Time frame:
Baseline, Day 15

No measurements were reported for this outcome.

SecondaryChange From Baseline in Tumor Tissue Biomarkers
Time frame:
Up to 15 months

No measurements were reported for this outcome.

Adverse events

Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Assigned—1/1 (100%)1/1 (100%)
COB 20 mg + GDC 200 mg—2/5 (40%)5/5 (100%)
COB 40 mg + GDC 200 mg—2/3 (66.7%)3/3 (100%)
COB 80 mg + GDC 200 mg—3/5 (60%)5/5 (100%)
COB 80 mg + GDC 400 mg—2/4 (50%)4/4 (100%)
COB 100 mg + GDC 200 mg—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
ABDOMINAL PAINGastrointestinal disorders1/10/50/30/50/40/6
PNEUMONIA VIRALInfections and infestations1/10/50/30/50/40/6
HYPOXIARespiratory, thoracic and mediastinal disorders1/10/50/30/50/40/6
DIARRHOEAGastrointestinal disorders0/10/51/30/50/41/6
ANAEMIABlood and lymphatic system disorders0/10/51/30/50/40/6
DYSPHAGIAGastrointestinal disorders0/10/50/30/51/40/6
NAUSEAGastrointestinal disorders0/10/50/30/51/40/6
OEDEMA PERIPHERALGeneral disorders0/10/50/30/51/40/6
DEHYDRATIONMetabolism and nutrition disorders0/10/50/30/51/40/6
COLITISGastrointestinal disorders0/10/50/31/50/40/6
Most frequent other events
Showing 10 of 131
Most frequent other events
EventNot AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mg
DIARRHOEAGastrointestinal disorders1/14/52/35/54/44/6
NAUSEAGastrointestinal disorders1/15/52/34/53/42/6
VOMITINGGastrointestinal disorders1/13/51/35/53/43/6
DYSPNOEARespiratory, thoracic and mediastinal disorders1/11/50/31/51/41/6
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders1/12/52/31/54/41/6
RASHSkin and subcutaneous tissue disorders1/11/51/30/50/41/6
FATIGUEGeneral disorders0/14/51/32/52/43/6
VISION BLURREDEye disorders0/12/51/30/53/41/6
HAEMATOCHEZIAGastrointestinal disorders0/11/52/30/50/40/6
ASTHENIAGeneral disorders0/13/52/30/51/40/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Not AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mgTotal
Mean48.0 ± 999953.0 ± 11.557.3 ± 11.051.6 ± 14.252.3 ± 5.659.7 ± 11.554.6 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Not AssignedCOB 20 mg + GDC 200 mgCOB 40 mg + GDC 200 mgCOB 80 mg + GDC 200 mgCOB 80 mg + GDC 400 mgCOB 100 mg + GDC 200 mgTotal
Female05342317
Male1001237
08

Study locations

5 sites
  • University of Colorado
    Aurora, Colorado 80045-2517, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Dec 2016, 17 months.

Results were first posted in Aug 2018, 1 year 8 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 17 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2015
First posted
May 29, 2015
StartActual
Jun 16, 2015
Primary completionActual
Dec 5, 2016
CompletionActual
Dec 5, 2016
Results first posted
Aug 24, 2018
Last update
Nov 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02457793
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 29, 2015
Start date
Jun 16, 2015
Primary completion
Dec 5, 2016
Completion
Dec 5, 2016
Results posted
Aug 24, 2018
Last update
Nov 20, 2018

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion